These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34855643)

  • 21. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis.
    Kale-Pradhan PB; Mihaescu A; Wilhelm SM
    Pharmacotherapy; 2015 Aug; 35(8):719-30. PubMed ID: 26173786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital.
    Dib J; Alvarez B; Mendez L; Cruz ME
    Arab J Gastroenterol; 2013 Sep; 14(3):123-5. PubMed ID: 24206741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
    Greenberg ER; Anderson GL; Morgan DR; Torres J; Chey WD; Bravo LE; Dominguez RL; Ferreccio C; Herrero R; Lazcano-Ponce EC; Meza-Montenegro MM; Peña R; Peña EM; Salazar-Martínez E; Correa P; Martínez ME; Valdivieso M; Goodman GE; Crowley JJ; Baker LH
    Lancet; 2011 Aug; 378(9790):507-14. PubMed ID: 21777974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.
    Xin Y; Manson J; Govan L; Harbour R; Bennison J; Watson E; Wu O
    BMC Gastroenterol; 2016 Jul; 16(1):80. PubMed ID: 27460211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.
    Gisbert JP; Gonzalez L; Calvet X
    Helicobacter; 2005 Jun; 10(3):157-71. PubMed ID: 15904473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials.
    Peedikayil MC; Alsohaibani FI; Alkhenizan AH
    PLoS One; 2014; 9(1):e85620. PubMed ID: 24465624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
    Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
    BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
    Sun Y; Yue L; Hu W
    Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.
    Kate V; Kalayarasan R; Ananthakrishnan N
    Drugs; 2013 Jun; 73(8):815-24. PubMed ID: 23625272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
    Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
    Lee H; Hong SN; Min BH; Lee JH; Rhee PL; Lee YC; Kim JJ
    Dig Liver Dis; 2015 Feb; 47(2):114-8. PubMed ID: 25467826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
    Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication.
    Yeo YH; Hsu CC; Lee CC; Ho HJ; Lin JT; Wu MS; Liou JM; Wu CY;
    J Gastroenterol Hepatol; 2019 Jan; 34(1):59-67. PubMed ID: 30169908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
    Lu K; Lang C; Zou X; Zang L; Sang W; Feng Q; Mu Y; Liu L; Xu C; Zhao J
    Trials; 2023 Jun; 24(1):413. PubMed ID: 37337241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial.
    Ladrón-de-Guevara L; Bornstein-Quevedo L; González-Huezo S; Castañeda-Romero B; Costa FG; di Silvio-López M
    Rev Gastroenterol Mex (Engl Ed); 2019; 84(3):274-283. PubMed ID: 30060902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.